Latest Information Update: 20 Dec 2012
At a glance
- Originator ReceptoPharm
- Developer Bio Therapeutics
- Mechanism of Action Nicotinic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 18 Dec 2012 Discontinued - Phase-I for Pain in USA (PO)
- 26 Mar 2007 Phase-I clinical trials in Pain in USA (PO)